Given the patient's current medication regimen, which potential drug interaction could lead to increased risk of adverse effects due to shared metabolic pathways?
Simvastatin and Alendronic acid, both affecting bone density, increasing fracture risk. Leucovorin and Oxaliplatin, both used in chemotherapy, causing cumulative toxicity. Alendronic acid and Simvastatin, both affecting calcium metabolism, leading to hypercalcemia. Simvastatin and Galantamine, both metabolized by CYP3A4, increasing the risk of side effects.